. 2024 Mar 12;10(1):e003839. doi: 10.1136/rmdopen-2023-003839

Table 2.

Logistic regression for VAS pain score of ≤10 and ≤20 mm at week 24: single-variable analysis with pairwise comparison

Baseline parameter	Pairwise comparison	VAS pain score ≤10 mm		VAS pain score ≤20 mm
Baseline parameter	Pairwise comparison	OR (95% CI)	P value	OR (95% CI)	P value
Age, years	1 unit increase	1.00 (0.99 to 1.00)	0.322*	0.99 (0.99 to 1.00)	0.006
Anti-CCP or RF positive	Yes vs no	1.52 (1.20 to 1.91)	<0.001	1.47 (1.20 to 1.80)	<0.001
BMI, kg/m²	1 unit increase	0.98 (0.97 to 1.00)	0.028	0.98 (0.97 to 0.99)	<0.001
CRP, mg/L	1 unit increase	1.00 (1.00 to 1.01)	0.440*	1.00 (1.00 to 1.00)	0.710*
CDAI	1 unit increase	0.99 (0.98 to 1.00)	0.001	0.99 (0.98 to 0.99)	<0.001
Concurrent oral corticosteroids	Yes vs no	0.83 (0.70 to 0.99)	0.040	0.82 (0.71 to 0.96)	0.013
DAS28-CRP	1 unit increase	0.88 (0.79 to 0.98)	0.018	0.86 (0.78 to 0.95)	0.003
Duration of RA, years	1 unit increase	0.98 (0.97 to 1.00)	0.009	0.99 (0.98 to 1.00)	0.027
Ethnicity	Hispanic/Latino vs not Hispanic/Latino	1.48 (1.19 to 1.84)	<0.001	1.23 (1.01 to 1.51)	0.040
FACIT-Fatigue	1 unit increase	1.03 (1.02 to 1.04)	<0.001	1.03 (1.02 to 1.04)	<0.001
HAQ-DI	1 unit increase	0.65 (0.55 to 0.77)	<0.001	0.72 (0.62 to 0.84)	<0.001
Patient global VAS score, mm	1 unit increase	0.99 (0.98 to 1.00)	0.013	0.99 (0.98 to 0.99)	<0.001
Physician global VAS score, mm	1 unit increase	1.00 (0.99 to 1.00)	0.140*	0.99 (0.99 to 1.00)	0.002
Prior exposure to bDMARDs	Yes vs no	0.65 (0.31 to 1.37)	0.258*	0.63 (0.34 to 1.19)	0.158*
Race	Asian vs White	0.93 (0.75 to 1.15)	0.496	1.12 (0.93 to 1.35)	0.221
	Black/African American vs White	0.94 (0.57 to 1.55)	0.803	0.67 (0.42 to 1.06)	0.084
	Other vs White	1.65 (1.22 to 2.25)	0.001	1.50 (1.13 to 2.00)	0.005
	Overall	–	0.007	–	0.006
SJC28/TJC28 ratio	1 unit increase	1.09 (0.98 to 1.20)	0.099*	1.12 (0.99 to 1.27)	0.082*
Region	Asia+Southeast Asia vs North America	0.84 (0.64 to 1.10)	0.206	1.19 (0.94 to 1.52)	0.154
	Eastern Europe vs North America	0.75 (0.59 to 0.97)	0.027	1.00 (0.80 to 1.26)	0.974
	South/Central America vs North America	1.56 (1.16 to 2.12)	0.004	1.72 (1.29 to 2.28)	<0.001
	Western Europe+Other vs North America	1.09 (0.80 to 1.50)	0.575	1.07 (0.80 to 1.43)	0.654
	Overall	–	<0.001	–	<0.001
	North America vs rest of world	1.06 (0.86 to 1.32)	0.580*	0.86 (0.71 to 1.05)	0.136*
SDAI	1 unit increase	0.99 (0.98 to 1.00)	0.003	0.99 (0.98 to 0.99)	<0.001
SF-36 MCS	1 unit increase	1.02 (1.02 to 1.03)	<0.001	1.02 (1.01 to 1.03)	<0.001
SF-36 PCS	1 unit increase	1.05 (1.03 to 1.06)	<0.001	1.04 (1.03 to 1.06)	<0.001
Sex	Female vs male	0.77 (0.63 to 0.94)	0.012	0.92 (0.76 to 1.11)	0.370*
Smoking status	Current vs never	1.28 (1.00 to 1.63)	0.050	1.14 (0.92 to 1.43)	0.239
	Former vs never	1.78 (1.40 to 2.25)	<0.001	1.53 (1.22 to 1.91)	<0.001
	Overall	–	<0.001	–	<0.001
SJC28	1 unit increase	1.00 (0.98 to 1.01)	0.724*	0.99 (0.98 to 1.01)	0.206*
TJC28	1 unit increase	0.97 (0.96 to 0.98)	<0.001	0.97 (0.96 to 0.98)	<0.001

The model included treatment group, study, baseline pain VAS score and one of the additional predictors shown.

*Predictor ineligible for multivariable model (p≥0.05).

Anti-CCP, anti-cyclic citrullinated peptide; bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, Disease Activity Score-28 with C-reactive protein; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI, Health Assessment Questionnaire–Disability Index; MCS, mental component summary score; PCS, physical component summary score; RF, rheumatoid factor; SDAI, Simple Disease Activity Index; SF-36, 36-item short-form health survey; SJC28, swollen joint count based on 28 joints; TJC28, tender joint count based on 28 joints; VAS, visual analogue scale.